Hematology

Latest News

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Donating blood can save more than 1 life | image credit: Creative Cat Studio - stock.adobe.com
5 Things to Know About Donating Blood

January 10th 2025

mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com
Study Advocates Immunological Value of COVID-19 Vaccination in MM

January 9th 2025

MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com
MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

January 6th 2025

Among 55 evaluable samples analyzed, QPOP achieved an 87.3% success rate in generating individualized drug sensitivity reports. | Image credit: Eleni - stock.adobe.com
Functional Precision Medicine Tool Predicts Treatment Response in AML

January 6th 2025

More News

FORTE Trial: Transplant in Patients with Multiple Myeloma
June 28th 2019

FORTE Trial: Transplant in Patients with Multiple Myeloma

Impact of Maintenance Therapy in Multiple Myeloma
June 28th 2019

Impact of Maintenance Therapy in Multiple Myeloma

Strategy for Up-front Therapy of Multiple Myeloma
June 28th 2019

Strategy for Up-front Therapy of Multiple Myeloma

Backbone Therapy in Newly Diagnosed Multiple Myeloma
June 28th 2019

Backbone Therapy in Newly Diagnosed Multiple Myeloma

How Real-World Data Can Address Problems in MM
June 28th 2019

How Real-World Data Can Address Problems in MM

Dosing Strategies in Relapsed-Refractory MM
June 28th 2019

Dosing Strategies in Relapsed-Refractory MM

Initiating Treatment in Relapsed-Refractory MM
June 28th 2019

Initiating Treatment in Relapsed-Refractory MM

What Is the Cost of Recurrence in Multiple Myeloma?
June 28th 2019

What Is the Cost of Recurrence in Multiple Myeloma?

Daratumumab in the Treatment Landscape for MM
June 28th 2019

Daratumumab in the Treatment Landscape for MM

Clinical Significance of MRD Testing in MM
June 28th 2019

Clinical Significance of MRD Testing in MM

Practical Implications of the MAIA Study for MM
June 28th 2019

Practical Implications of the MAIA Study for MM

Considerations for Transplant-Ineligible Patients
June 28th 2019

Considerations for Transplant-Ineligible Patients

NCCN Guidelines for Newly Diagnosed MM
June 28th 2019

NCCN Guidelines for Newly Diagnosed MM

Achieving the Best Outcomes for Patients With MM
June 28th 2019

Achieving the Best Outcomes for Patients With MM

Cost Considerations of Multidrug Regimens in MM
June 28th 2019

Cost Considerations of Multidrug Regimens in MM

Factoring Age Into Frontline Therapy for MM
June 28th 2019

Factoring Age Into Frontline Therapy for MM

Individualizing Therapy for Multiple Myeloma Patients
June 28th 2019

Individualizing Therapy for Multiple Myeloma Patients

Gait Speed Accurately Predicts Outcomes for Elderly Patients With Hematologic Malignancies
June 27th 2019

Gait Speed Accurately Predicts Outcomes for Elderly Patients With Hematologic Malignancies

Samantha DiGrande
According to a new study, the speed at which older patients with blood cancers are able to walk nearly 13 feet (about 4 meters) contains important information about their overall health and may be able to help predict survival and unplanned hospital visits.
FDA Lifts Partial Clinical Hold on Phase 3 Venetoclax Study for Patients With Multiple Myeloma
June 25th 2019

FDA Lifts Partial Clinical Hold on Phase 3 Venetoclax Study for Patients With Multiple Myeloma

Wallace Stephens
Based upon an agreement that study protocol would be revised, the FDA has removed the partial clinical hold it placed in March on CANOVA, a phase 3 clinical trial of venetoclax.
How Could Early Treatment Benefit Patients With Smoldering Multiple Myeloma?
June 22nd 2019

How Could Early Treatment Benefit Patients With Smoldering Multiple Myeloma?

Wallace Stephens
Early treatment, in comparison to deferred treatment, of patients with smoldering multiple myeloma could reduce progression and mortality.
Dr Thomas Marsland on CMS' CAR T-Cell Therapy Reimbursement Plan
June 21st 2019

Dr Thomas Marsland on CMS' CAR T-Cell Therapy Reimbursement Plan

Thomas Marsland, MD, medical oncologist, discusses his take on the CAR T-cell therapy reimbursement plan put forward by CMS.
Isatuximab Combination Improves PFS in Relapsed, Refractory MM
June 15th 2019

Isatuximab Combination Improves PFS in Relapsed, Refractory MM

Samantha DiGrande
According to results from a randomized phase 3 trial presented at the American Society of Clinical Oncology’s recent annual meeting, the addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improvement progression-free survival (PFS) and the overall response rate (ORR) in patients with relapsed or refractory multiple myeloma (RRMM).
Survival of Patients With Multiple Myeloma Has Continued to Improve
June 13th 2019

Survival of Patients With Multiple Myeloma Has Continued to Improve

Wallace Stephens
Survival of patients with multiple myeloma has continued to improve as treatments have evolved over time.
Multimorbidity, Insurance Status May Affect Survival Rates of Patients With Multiple Myeloma
June 8th 2019

Multimorbidity, Insurance Status May Affect Survival Rates of Patients With Multiple Myeloma

Wallace Stephens
According to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting, multimorbidity, insurance status, and income may affect survival rates of patients with multiple myeloma.
5 Takeaways From ASCO's Annual Meeting
June 7th 2019

5 Takeaways From ASCO's Annual Meeting

Samantha DiGrande
The American Society of Clinical Oncology recently held its annual meeting in Chicago, Illinois. The meeting brought together oncologists, payers, and other stakeholders to discuss the latest updates and therapeutic advances in cancer care. Here are 5 of the biggest takeaways from the meeting.
Adding Daratumumab to Standard Treatment Lowered the Risk of Death, Disease Progression in Patients With Multiple Myeloma
May 31st 2019

Adding Daratumumab to Standard Treatment Lowered the Risk of Death, Disease Progression in Patients With Multiple Myeloma

Wallace Stephens
The addition of daratumumab to standard treatment of lenalidomide and dexamethasone for patients with multiple myeloma, who were ineligible for autologous stem-cell transplant, was found to significantly lower the risk of disease progression or death compared with those who only received standard treatment.
Patients With Prior Hematologic Malignancy at Increased Risk for Head and Neck Cancer, Study Finds
May 31st 2019

Patients With Prior Hematologic Malignancy at Increased Risk for Head and Neck Cancer, Study Finds

Samantha DiGrande
According to results from a recent retrospective study, patients previously diagnosed with a hematologic malignancy were found to be at a higher risk of developing head and neck cancers compared with patients without a prior hematologic malignancy.
Is Sickle Cell Trait Associated With Cognitive Impairment in African Americans?
May 25th 2019

Is Sickle Cell Trait Associated With Cognitive Impairment in African Americans?

Wallace Stephens
Analysis of findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study found no association between sickle cell trait and cognitive impairment.
Lenalidomide Beats Standard of Care in Smoldering MM
May 23rd 2019

Lenalidomide Beats Standard of Care in Smoldering MM

Samantha DiGrande
As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, according to new research that will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, Illinois, held May 31 to June 4, early treatment of smoldering MM may delay progression to full-blown disease.
Venetoclax Gains FDA Approval for Previously Untreated CLL, SLL
May 16th 2019

Venetoclax Gains FDA Approval for Previously Untreated CLL, SLL

Jaime Rosenberg
Venetoclax (Venclexta) has received FDA approval in combination with obinutuzumab (Gazyva) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), offering a chemotherapy-free regimen for patients with previously untreated disease.
<1
...
8910111213141516
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo